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Abstract
Previous studies of fetal death with maternal influenza have been inconsistent. We explored the effect of maternal influenza-like 
illness (ILI) in pregnancy on the risk of fetal death, distinguishing between diagnoses during regular influenza seasons and the 
2009/2010 pandemic and between trimesters of ILI. We used birth records from the Medical Birth Registry of Norway to identify 
fetal deaths after the first trimester in singleton pregnancies (2006–2013). The Norwegian Directorate of Health provided dates of 
clinical influenza diagnoses by primary-health-care providers, whereas dates of laboratory-confirmed influenza A (H1N1) diagnoses 
were provided by the Norwegian Surveillance System for Communicable Diseases. We obtained dates and types of influenza vac-
cinations from the Norwegian Immunisation Registry. Cox proportional-hazards regression models were fitted to estimate hazard 
ratios (HRs) of fetal death, with associated 95% confidence intervals (CIs), comparing women with and without an ILI diagnosis 
in pregnancy. There were 2510 fetal deaths among 417,406 eligible pregnancies. ILI during regular seasons was not associated 
with increased risk of fetal death: adjusted HR = 0.90 (95% CI 0.64–1.27). In contrast, ILI during the pandemic was associated with 
substantially increased risk of fetal death, with an adjusted HR of 1.75 (95% CI 1.21–2.54). The risk was highest following first-
trimester ILI (adjusted HR = 2.28 [95% CI 1.45–3.59]). ILI during the pandemic—but not during regular seasons—was associated 
with increased risk of fetal death in the second and third trimester. The estimated effect was strongest with ILI in first trimester.
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Introduction
Several previous studies have assessed associations between 
maternal influenza virus infection in pregnancy and adverse 
maternal and pregnancy outcomes [1, 2].
Pregnant women are at increased risk of morbidity 
related to seasonal influenza [3–5]. However, there is con-
flicting evidence of associations with perinatal outcomes, 
as findings are inconsistent across studies [6–10]. A US 
study of respiratory illness in pregnant women found no 
statistically significant association between respiratory hos-
pitalization during influenza seasons in 1985–1993 and fetal 
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death [7]. In a Danish study of the temporal association 
between influenza activity and frequency of fetal death in 
1994–2009, there was no statistically significant correla-
tion between time series of weekly influenza-like illness 
(ILI) consultation proportions and time series of weekly 
proportions of spontaneous abortions or stillbirths [11]. 
On the other hand, a US study of pregnant women hos-
pitalized during influenza seasons in 1998–2008 demon-
strated increased odds of intrauterine fetal demise among 
delivery hospitalizations complicated by respiratory illness 
compared to non-respiratory delivery hospitalizations [12]. 
However, this study was considered to be at a very high risk 
of diagnostic ascertainment bias [2].
Maternal morbidity and adverse pregnancy and neona-
tal outcomes have been associated with 2009 pandemic 
influenza A virus subtype H1N1 (influenza A[H1N1]
pdm09) infection in pregnancy [13–15]. A UK study 
reported an association between maternal inf luenza 
A(H1N1)pdm09 infection in pregnancy and increased 
risk of fetal death from 24 weeks [16], but the risk of 
diagnostic ascertainment bias for this study has been con-
sidered high [2]. In a Chinese study of maternal influ-
enza A(H1N1)pdm09 infection in pregnancy, stillbirth 
was more frequent among women who tested positive for 
virus-specific antibodies compared to women who tested 
negative [17]. Furthermore, the risk of fetal death was 
increased following a primary-health-care diagnosis of 
influenza in pregnancy during the “swine flu” pandemic 
in 2009/2010 in Norway [18].
The main objective of the current study was to assess 
the risk of fetal death associated with maternal ILI in preg-
nancy during the influenza seasons between 2006 and 2013. 
In addition, we aimed to explore the associations by trimes-
ter of ILI.
Methods
We used individual-level data from Norwegian nationwide 
health registries. The data sources were linked by the unique 
personal identification number assigned to every resident of 
Norway.
Fetal death
The Medical Birth Registry of Norway (MBRN) con-
tains data on births after 12 completed weeks of preg-
nancy, including detailed information about the mother, 
the pregnancy, the delivery, and the child. Fetal death 
was defined as any fetal loss, i.e., spontaneous abor-
tion (miscarriage) or stillbirth, from the 12th completed 
gestational week onwards. We used the MBRN to iden-
tify fetal deaths in the second and third trimester in the 
years 2006–2013.
Influenza seasons
The Norwegian Institute of Public Health (NIPH) is 
responsible for monitoring the influenza activity in Nor-
way throughout the whole year [19, 20]. However, the sur-
veillance of medical consultations in primary health care 
related to ILI is restricted from calendar week 40 (end of 
September or beginning of October) to calendar week 20 
(middle of May). We considered nine different influenza sea-
sons from 2006 (including the 2005/2006 season) through 
2013 (including the 2013/2014 season). All seasons coin-
cided with the NIPH’s annual surveillance of influenza-
related medical consultations but the pandemic season in 
2009/2010, which we defined from mid-May 2009 to mid-
May 2010.
Influenza‑like illness
In Norway, all consultation dates and diagnoses made by 
a general practitioner in primary health care are reported 
to the Norwegian Directorate of Health for reimbursement 
purposes [21]. Diagnoses are coded using the International 
Classification of Primary Care, Second Edition (ICPC-2) 
[22]. We obtained data on all women diagnosed with ICPC-2 
code R80 (“influenza”) in 2006–2013. Furthermore, data on 
women with a laboratory-confirmed diagnosis of influenza 
A (H1N1) virus infection, i.e., “swine flu”, in 2009–2011 
were obtained from the Norwegian Surveillance System for 
Communicable Diseases (MSIS).
The R80 diagnosis from primary health care is based on 
several clinical criteria of influenza symptoms occurring 
within an influenza outbreak. Criteria for the R80 code are 
given in Online Resource 1. We only included R80 diag-
noses made during the predefined influenza seasons. Thus, 
we discarded all “off-season” R80 diagnoses. Laboratory-
confirmed influenza A (H1N1) diagnoses were, however, 
considered reliable regardless of whether they were given 
within or outside the influenza seasons in question; all 
laboratory-confirmed diagnoses before July 1, 2010, were 
attributed to the 2009/2010 pandemic season (first observed 
diagnosis on June 10, 2009), and all laboratory-confirmed 
diagnoses from July 1, 2010, onwards were attributed to the 
subsequent season in 2010/2011 (last observed diagnosis on 
April 5, 2011). We considered ILI as either an R80 diagnosis 
or a laboratory-confirmed influenza A (H1N1) diagnosis.
Following the 2009/2010 pandemic season, influenza 
A(H1N1)pdm09 was regarded as one of the seasonal 
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influenza strains, and infection with this virus subtype vari-
ant was thereafter considered as regular seasonal influenza. 
Hence, we defined pandemic influenza as ILI related to the 
2009/2010 season and seasonal influenza as ILI related to 
any of the other eight influenza seasons under study, regard-
less of the circulating strains.
Influenza vaccination
Data on vaccination against influenza virus were provided 
by the Norwegian Immunisation Registry (SYSVAK) from 
2006 through the beginning of 2013 [23]. Influenza vac-
cinations were not notifiable prior to the “swine flu” pan-
demic in 2009/2010, during which reporting of all influ-
enza vaccinations to SYSVAK was mandatory and nearly 
complete. After the pandemic, that is, from the 2010/2011 
season onwards, influenza vaccinations have been notifiable 
provided that oral consent is obtained from each vaccinee or 
parent/guardian [23]. Hence, there has been a considerable 
underreporting of influenza vaccinations during regular sea-
sons. Therefore, we only considered vaccinations with Pan-
demrix  H1N1® (GlaxoSmithKline) and  Celvapan® (Baxter), 
which were vaccines used during the pandemic influenza 
outbreak. The proportion between the two vaccination types 
in the current study was 2.2  Celvapan® vaccinations per 
10 000 Pandemrix  H1N1® vaccinations. These will hereafter 
be referred to as pandemic vaccinations.
Study sample
The MBRN data set (2006–2013) initially comprised 
486,008 birth records among 336,877 mothers. Birth records 
corresponding to induced abortions were not included. We 
discarded 3527 records with missing data on pregnancy 
onset due to missing length of gestation and 46,022 records 
with pregnancy onset before January 1, 2006, that is, before 
information about ILI diagnoses was available. We also dis-
carded 3321 records with pregnancy onset after March 5, 
2013, to make sure that all pregnancies under study had the 
potential of lasting 43 completed weeks (301 days), thereby 
avoiding an oversampling of short pregnancies towards the 
end of 2013 due to right-truncation [18]. We further dis-
carded 9 records with missing or invalid maternal residen-
tial status as registered in the National Registry and 471 
records corresponding to maternal emigration before preg-
nancy onset or January 1, 2006. Moreover, we discarded 933 
records of live-born children born to foreign parents not liv-
ing in Norway and 158 records registered as live births but 
with gestational length less than 22 weeks or birth weight 
less than 500 g. In addition, we discarded 16,774 records 
with plurality greater than one or missing. Several birth 
records were discarded for more than one of the aforemen-
tioned reasons. Finally, our study sample comprised 417,406 
eligible singleton (i.e., non-plural) birth records (305,180 
mothers), of which 2510 records (0.6%) of fetal death. Char-
acteristics of the study sample are shown in Table 1.
Statistical analysis
We applied Cox proportional-hazards regression to esti-
mate crude and adjusted hazard ratios (HRs) of fetal death 
between different groups: women diagnosed with ILI at vari-
ous stages of pregnancy (any time in pregnancy, in the first 
trimester, and in the second or third trimester, respectively) 
and undiagnosed women. Associated 95% confidence inter-
vals (CIs) were obtained by using robust standard errors, 
allowing for intragroup correlation between birth records 
with shared mother (i.e., siblings).
Our time scale was the number of days since pregnancy 
onset, which was established by using information from the 
MBRN about date of birth and gestational length. The lat-
ter was based on estimations from an ultrasound scan, if 
available; otherwise, it was based on the first day of the last 
menstrual period, as reported by the mother. The event of 
interest was fetal death. We defined censoring as either a live 
birth, maternal emigration, or pregnancy day 301 (first day 
of the 43rd completed gestational week). The study period 
extended from January 1, 2006, to December 31, 2013, dur-
ing which data on both ILI and fetal death were available. As 
the study sample only included birth records with pregnancy 
onset up to, and including, March 5, 2013, no observations 
were censored due to end of study (December 31, 2013).
The exposures under study were seasonal and pandemic 
influenza during pregnancy. A woman was regarded as being 
exposed to a specific influenza type from the earliest date 
of an ILI diagnosis in pregnancy during a relevant season, 
designated as the type-specific ILI onset date, throughout 
the rest of her pregnancy. We fitted two different regression 
models. Model 1 included two indicator variables for having 
had seasonal/pandemic influenza at any time during preg-
nancy: ‘no’ or ‘yes’. In Model 2, we included two categorical 
variables for seasonal/pandemic influenza during pregnancy, 
incorporating the timing of the respective exposures: ‘no’, 
‘yes, in the first trimester’, or ‘yes, in the second or third 
trimester’. The influenza exposures were handled as time-
dependent variables, treating women as unexposed until the 
first pregnancy day of an ILI diagnosis.
To explore how the effects of seasonal and pandemic 
influenza might vary with time during the course of preg-
nancy, we conducted three separate sets of analyses of fetal 
death at different gestational stages. The main analyses con-
sidered fetal death at any time after the first trimester. In 
these analyses, women entered the risk set on pregnancy day 
84 (first day of the 12th completed gestational week) and 
were followed until either fetal death or censoring, which-
ever occurred first. In a set of supplementary analyses, we 
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Table 1  Characteristics of the 
study sample from the Medical 
Birth Registry of Norway 
(2006–2013)
Live births Fetal  deathsa Total number
Number Percentage Number Percentage
Total 414,896 99.4 2510 0.6 417,406
Year of birth
 2006b 12,011 98.4 191 1.6 12,202
 2007 56,027 99.3 377 0.7 56,404
 2008 58,128 99.4 372 0.6 58,500
 2009 59,487 99.5 320 0.5 59,807
 2010 59,122 99.4 345 0.6 59,467
 2011 58,122 99.4 340 0.6 58,462
 2012 58,109 99.4 325 0.6 58,434
 2013c 53,890 99.6 240 0.4 54,130
Gestational length (completed weeks)
 12–19 0 0.0 714 100.0 714
 20–27 901 54.6 748 45.4 1649
 28–35 11,470 96.6 398 3.4 11,868
 36–43 402,350 99.8 650 0.2 403,000
 ≥ 44 175 100.0 0 0.0 175
Maternal age (years)
 < 20 8645 99.3 65 0.7 8710
 20–24 60,702 99.5 310 0.5 61,012
 25–29 130,208 99.5 618 0.5 130,826
 30–34 135,832 99.4 795 0.6 136,627
 35–39 66,677 99.1 587 0.9 67,264
 ≥ 40 12,832 99.0 135 1.0 12,967
Maternal marital status
 Married/co-habitant 382,604 99.4 2209 0.6 384,813
 Other 32,292 99.1 301 0.9 32,593
Maternal parity
 0 175,831 99.5 961 0.5 176,792
 ≥ 1 239,065 99.4 1549 0.6 240,614
Maternal history of fetal death
 No 325,860 99.5 1734 0.5 327,594
 Yes 89,036 99.1 776 0.9 89,812
Maternal chronic  conditionsd
 No 366,145 99.4 2211 0.6 368,356
 Yes 48,751 99.4 299 0.6 49,050
Maternal use of nutritional supplements before and/or during pregnancy
 No 111,167 98.9 1256 1.1 112,423
 Yes 303,729 99.6 1254 0.4 304,983
Maternal smoking at the beginning of pregnancy
 No 311,389 99.4 1775 0.6 313,164
 Yes 103,507 99.3 735 0.7 104,242
Maternal seasonal influenza during pregnancy
 No 406,588 99.4 2477 0.6 409,065
 Yes 8308 99.6 33 0.4 8341
Trimester of maternal seasonal influenza during pregnancy
 No seasonal influenza during preg-
nancy
406,588 99.4 2477 0.6 409,065
 First trimester 3031 99.3 20 0.7 3051
 Second or third trimester 5277 99.8 13 0.2 5290
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studied fetal death in the second trimester only. As in the 
main analyses, we followed the women from pregnancy day 
84. Observations of women neither delivering nor emigrat-
ing during the second trimester were censored on pregnancy 
day 195 (last day of the 27th completed gestational week). 
Another set of supplementary analyses were restricted to 
fetal death in the third trimester. Here, women first entered 
the risk set on pregnancy day 196 (first day of the 28th com-
pleted gestational week). The last possible exit time in these 
analyses was on pregnancy day 301 (first day of the 43rd 
completed gestational week), as in the main analyses.
In some additional supplementary analyses, we also 
adjusted for pandemic vaccination. The study period for 
these analyses was restricted from May 15, 2009, to Sep-
tember 30, 2010, thereby including only the pandemic sea-
son and none of the regular influenza seasons. We fitted 
two regression models, Model 3 and Model 4 (analogous 
to Model 1 and Model 2, respectively), including exposure 
variables for pandemic influenza and pandemic vaccination. 
Seasonal influenza was not included in these analyses.
We obtained information on seven variables from the 
MBRN based on a priori considerations of potential con-
founders of the associations between maternal seasonal 
and pandemic influenza during pregnancy and fetal death. 
These included maternal age (‘< 20 years’, ‘20–24 years’, 
‘25–29 years’, ‘30–34 years’, ‘35–39 years’, or ‘≥ 40 years’), 
maternal marital status (‘married/co-habitant’ or ‘other’), 
maternal parity (‘0’ or ‘≥ 1’), maternal history of fetal death 
(‘no’ or ‘yes’), maternal chronic conditions such as asthma, 
chronic hypertension, chronic renal disease, rheumatoid 
arthritis, heart disease, epilepsy, diabetes, and thyroid dis-
ease (‘no’ or ‘yes’), maternal use of nutritional supplements 
before and/or during pregnancy (‘no’ or ‘yes’), and mater-
nal smoking at the beginning of pregnancy (‘no’ or ‘yes’). 
The variables were all included in the adjusted analyses as 
baseline covariates. In addition, we assumed that the current 
calendar quarter (‘January through March’, ‘April through 
June’, ‘July through September’, or ‘October through 
December’) might possibly also affect both the pregnant 
woman’s influenza status and the risk of fetal death. Thus, 
calendar quarter was included as a time-dependent covariate 
in the adjusted analyses to account for seasonal variation in 
the exposures and outcome.
Data were analyzed by using Stata SE 15 (StataCorp. 
2017. Stata Statistical Software: Release 15. College Sta-
tion, TX: StataCorp LLC).
Results
There were 2510 fetal deaths among the 417,406 eligible 
singleton birth records (6.0/1000). A total of 11,896 birth 
records (2.8%) were linked to maternal influenza during 
pregnancy: 8341 records (2.0%) to seasonal influenza and 
3581 records (0.9%) to pandemic influenza (Table 1). A few 
birth records (26, < 0.1%) were linked to both seasonal and 
pandemic influenza. There was a marked predominance of 
clinical R80 diagnoses from primary health care over lab-
oratory-confirmed H1N1 diagnoses among the ILI cases. 
During regular influenza seasons, 8327 birth records were 
registered with at least one maternal R80 diagnosis in preg-
nancy, compared to 41 birth records with at least one mater-
nal laboratory-confirmed H1N1 diagnosis in pregnancy. 
Corresponding numbers for the pandemic season were 3479 
and 518, respectively. There were too few fetal deaths among 
those with a laboratory-confirmed H1N1 diagnosis in preg-
nancy to conduct any sensitivity analyses restricted to such 
diagnoses.
The crude fetal mortality was 4.0 (95% CI 2.6–5.3) per 
1000 total births (i.e., live births and fetal deaths) among 
Table 1  (continued) Live births Fetal  deathsa Total number
Number Percentage Number Percentage
Maternal pandemic influenza during pregnancy
 No 411,343 99.4 2482 0.6 413,825
 Yes 3553 99.2 28 0.8 3581
Trimester of maternal pandemic influenza during pregnancy
 No pandemic influenza during preg-
nancy
411,343 99.4 2482 0.6 413,825
 First trimester 1387 98.6 19 1.4 1406
 Second or third trimester 2166 99.6 9 0.4 2175
a Spontaneous abortions (miscarriages) and stillbirths
b Excluding pregnancies with onset before January 1, 2006
c Excluding pregnancies with onset after March 5, 2013
d Asthma, chronic hypertension, chronic renal disease, rheumatoid arthritis, heart disease, epilepsy, diabe-
tes, or thyroid disease
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women diagnosed with seasonal influenza during preg-
nancy and 6.1 (95% CI 5.8–6.3) per 1000 total births among 
women not diagnosed with seasonal influenza. For pan-
demic influenza, the crude fetal mortality was 7.8 (95% CI 
4.9–10.7) and 6.0 (95% CI 5.8–6.2) per 1000 total births 
among diagnosed and undiagnosed women, respectively.
Results from the main analyses are displayed in Fig. 1. 
We found no evidence that maternal seasonal influenza dur-
ing pregnancy was associated with increased risk of fetal 
death after the first trimester, either overall (adjusted HR: 
0.90 [95% CI 0.64–1.27]) (Model 1) or by trimester of first 
ILI diagnosis during a regular influenza season (first-trimes-
ter adjusted HR: 1.13 [95% CI 0.73–1.76]; second- or third-
trimester adjusted HR: 0.69 [95% CI 0.40–1.19]) (Model 
2). On the other hand, the risk of fetal death was higher 
following maternal pandemic influenza during pregnancy 
(adjusted HR: 1.75 [95% CI 1.21–2.54]) (Model 1). This 
association seemed to be stronger with first ILI diagnosis 
during the pandemic season in the first trimester (adjusted 
HR: 2.28 [95% CI 1.45–3.59]) than in the second or third 
trimester (adjusted HR: 1.17 [95% CI 0.61–2.26]) (Model 2).
Results from supplementary analyses when restricting to 
fetal deaths in the second and third trimester, respectively, 
were similar to the main results (Supplementary Figs. 1 and 
2, Online Resource 2).
In the supplementary analyses restricted to the pandemic 
season in 2009/2010, the confounding effect of pandemic 
vaccination during pregnancy on the association between 
pandemic influenza during pregnancy and risk of fetal death 
was deemed negligible. Adjusting for pandemic vaccination 
only slightly changed the effect of pandemic influenza on 
the risk of fetal death—both overall (Model 3) and when 
considering the respective trimesters of first ILI diagnosis 
during the pandemic season and vaccination (Model 4) (Sup-
plementary Figs. 3–5, Online Resource 2).
The proportional-hazards assumption of the influenza 
exposures under study was tested on the basis of Schoenfeld 
residuals by using the   command in Stata after 
fitting the adjusted regression models. This involves testing 
that the log of the hazard ratio is constant over time. There 
was no evidence that the proportional-hazards assumption 
had been violated for any of the influenza variables in the 
adjusted main analyses; all corresponding p values in Model 
1 and Model 2 exceeded 0.05—both for seasonal influenza 
(overall: 0.46; first trimester: 0.13; second or third trimester: 
0.19) and for pandemic influenza (overall: 0.13; first trimes-
ter: 0.47; second or third trimester: 0.39).
Discussion
Maternal pandemic influenza during pregnancy—especially 
in the first trimester—was associated with a substantial 
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1Spontaneous abortions (miscarriages) and stillbirths.
2Ajustment for maternal age, maternal marital status, maternal parity, maternal history of fetal death, maternal chronic conditions (asthma, chronic hypertension, chronic renal disease, rheumatoid arthritis, heart disease,
epilepsy, diabetes, or thyroid disease), maternal use of nutritional supplements before and/or during pregnancy, and maternal smoking at the beginning of pregnancy as baseline covariates and calendar season and 
maternal seasonal/pandemic influenza as time−dependent covariates.
Fetal Death after the First Trimester with Seasonal and Pandemic Influenza
Fig. 1  Hazard ratios (HRs) of fetal death in the second or third tri-
mester, with associated 95% confidence intervals (CIs), between 
women with and without a diagnosis of influenza-like illness in preg-
nancy during regular influenza seasons (seasonal influenza) and with 
and without a diagnosis of influenza-like illness in pregnancy during 
the 2009/2010 pandemic season (pandemic influenza), respectively. 
Estimated by using Cox proportional-hazards regression with follow-
up between January 1, 2006, and December 31, 2013. Adjusted HRs 
also displayed graphically to the far right
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suggest that the risk of fetal death following ILI during the 
pandemic season remained elevated throughout the entire 
pregnancy.
The literature is inconsistent with regard to an effect of 
influenza on fetal mortality during previous pandemics. A 
US study of influenza in pregnant women during the “Span-
ish flu” pandemic of 1918/1919 showed that interruption 
of pregnancy (spontaneous abortion or preterm birth) was 
52% among cases in which influenza was complicated by 
pneumonia, compared to 26% among uncomplicated influ-
enza cases [24]. In a study of pregnant women in England 
during the “Asian flu” pandemic of 1957, there was no clear 
evidence of increased stillbirths following influenza in preg-
nancy [25]. A US study of “Asian flu” also found no increase 
in stillbirths [26]. No statistically significant difference in the 
incidence of fetal deaths between infected and uninfected 
women was found in a US study of teratogenic effects of 
pandemic “Asian flu” during pregnancy [27]. However, in 
another US study of the same outbreak, spontaneous abor-
tions and stillbirths were more frequent in women infected 
during their first trimester than those afflicted later in preg-
nancy or in uninfected women [28].
In contrast with our results for pandemic influenza, we 
found no evidence that maternal ILI during regular seasonal 
influenza increased the risk of fetal death. There are several 
possible explanations. The effects of infection may differ 
by the strain of influenza. It would have been of interest to 
separate strains, but, unfortunately, such information was 
not available in the current study. However, this explanation 
seems unlikely in that influenza virus from the H1N1 strain 
was circulating during several of the regular influenza sea-
sons following the “swine flu” pandemic of 2009/2010 [29].
Another possible explanation is that pandemic influenza 
virus infections may be more severe, perhaps due to reduced 
immunity in the population against the new (pandemic) 
viruses. In Norway, the prevalence of preexisting protective 
antibodies to the 2009 pandemic influenza A(H1N1) virus 
(hemagglutination inhibition [HI] titer ≥ 40) among adults 
aged 20–29 years and 30–49 years in August 2008 were only 
3.9% and 1.3%, respectively [30].
The current study extends a previous Norwegian study 
based on data from the same registries and databases but 
restricted to pregnancies during the pandemic influenza out-
break of 2009/2010 [18]. By extending the study period, 
we were able to include non-pandemic influenza seasons as 
well. We also considered trimester-specific effects of ILI. 
The previous study found pandemic influenza in pregnancy 
to be associated with increased risk of fetal death, whereas 
there was no apparent effect of pandemic vaccination on the 
risk of fetal death [18]. In the current study, the risk of fetal 
death appeared to be somewhat higher with ILI in the first 
trimester during the pandemic season.
A major strength of our study was the use of individ-
ual-level data from independent, mandatory registries with 
nationwide coverage and high data quality. For instance, the 
validity of diagnoses of unexplained antepartum fetal death 
as registered in the MBRN has previously been found to be 
sufficiently high for large-scale epidemiologic studies [31]. 
Large population-based registries are crucial to the surveil-
lance of a variety of exposures and outcomes, particularly 
when clinical trials are not possible. Moreover, many small-
sample studies are hampered by low statistical power—espe-
cially in the case of rare exposures or outcomes. This is less 
of a concern in large registry-based studies.
Another important strength of the current study was that 
all analyses were conducted by using Cox proportional-haz-
ards regression with time-dependent exposure variables. By 
choosing a time-to-event approach, we were able to take the 
time aspect of the exposure (influenza during pregnancy) 
and the outcome (fetal death) into account, thereby avoiding 
potential immortal time bias (also known as time-depend-
ent bias), where time at risk of outcome before exposure is 
misclassified as being associated with the exposure [32]. 
Furthermore, we could explore whether the effects of the 
trimester-specific influenza exposures differed across trimes-
ters based on separate analyses of fetal death restricted to the 
second and third trimester, respectively.
A limitation of our study was uncertainty related to the 
accuracy of influenza diagnoses from primary health care. 
More precisely, we lacked confirmation that the R80 diag-
noses reflected true influenza infections, as they are based 
mostly on clinical symptoms and not routinely laboratory-
confirmed. However, other ICPC-2 codes for unspecific 
symptoms such as “upper respiratory infection, acute” 
(R74), “cough” (R05), and “fever” (A03) are much more 
commonly used in primary health care, suggesting that a 
code for influenza is based on a more thorough evaluation 
of the clinical picture. Although only a small fraction of 
patients had laboratory confirmation of influenza, primary-
health-care physicians are instructed to consider whether 
there is influenza in close contacts or an ongoing influenza 
epidemic, in addition to other relevant criteria for influenza, 
before assigning a diagnosis (Online Resource 1). Even so, 
some R80 diagnoses may be a result of similar symptoms 
caused by other respiratory viruses (i.e., differential diag-
noses of influenza virus infection). To increase the reli-
ability of influenza infections, we therefore discarded all 
R80 diagnoses in pregnancy made outside the predefined 
influenza seasons under study. This reduced the number of 
birth records in the study sample with at least one influenza 
diagnosis in pregnancy by 6.5%: from 12,728 to 11,896 birth 
records. Moreover, all influenza diagnoses were limited to 
women seeking medical care, and with that, we no doubt 
misclassified cases of asymptomatic/subclinical or mild, 
less severe infections of influenza as unexposed. Hence, we 
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expect the current study to reflect associations with more 
severe influenza.
Our study lacked information about fetal losses in the first 
trimester, which made it impossible to address acute effects 
of maternal ILI occurring early in pregnancy. However, as 
we found increased risk of later fetal death with pandemic 
influenza in the first trimester, there is a possibility that this 
effect also increased losses in the first trimester. If so, we 
have underestimated the overall risk of fetal death associated 
with first-trimester ILI during the pandemic season.
An additional limitation of our study was not being able 
to make a proper adjustment for influenza vaccination due to 
the lack of complete information on all vaccinations against 
influenza virus. During the pandemic, about 90% of all vac-
cinees receiving at least one dose of vaccine against 2009 
pandemic influenza were registered in SYSVAK [23]. The 
estimated annual seasonal influenza vaccine coverage in the 
general Norwegian population in 2006–2017 was approxi-
mately 10% (unpublished data based on distributed doses, 
unused doses, and vaccinations registered in SYSVAK). 
Uptake is likely to be higher in defined risk groups. It is con-
ceivable that vaccination might affect the risk of fetal death 
while simultaneously reducing the risk of ILI in the preg-
nant woman, thereby confounding the association between 
maternal influenza during pregnancy and risk of fetal death. 
However, the low completeness of seasonal influenza vac-
cinations reported to SYSVAK limited our ability to include 
these in our study. Pandemic vaccination has previously been 
shown not to be associated with increased risk of fetal death 
[18]. Accordingly, adjustment for pandemic vaccination in 
the current study had little impact on the estimates for pan-
demic influenza in the supplementary analyses restricted 
to mid-May 2009 through September 2010, indicating that 
pandemic vaccination may not be an important confounder 
in this respect.
The MBRN requires registration of pregnancy losses 
at 12 completed weeks or more. Fetal deaths before that 
time could not be included in our study. Even starting at 
12 weeks, pregnancy losses are probably under-ascertained 
in the earliest weeks of the second trimester. Thus, some 
early second-trimester fetal deaths are likely to be missing 
from our study sample. If registrations of early pregnancy 
losses from birth clinics were dependent on the mothers 
being diagnosed with influenza in primary health care, our 
results could be inflated. However, the registries are man-
aged independently, and the increased risk after infection 
was present throughout pregnancy, making this potential 
bias less of a concern.
This study demonstrates the strengths and importance of 
nationwide population-based registries. It also indicates that 
such databases must be improved and expanded in order to 
fully meet the needs of public-health surveillance.
Future studies should attempt to address the biological 
and pathogenic mechanisms underlying the relation between 
maternal influenza virus infection in pregnancy and fetal 
death, with pandemic influenza virus infection being of spe-
cial interest. Such mechanisms might include transplacental 
transmission of the virus as well as transmission of inflam-
mation products and maternal antibodies. There is also a 
need to explore the possibility of fetal losses in the first tri-
mester with first-trimester infection.
In conclusion, there was no evidence of any increase in 
the risk of fetal death in the second or third trimester with 
maternal seasonal influenza. However, we found a more 
than twofold increased risk of fetal death following mater-
nal pandemic influenza in the first trimester, supporting that 
influenza during the pandemic season in 2009/2010 was a 
more severe threat to the fetus than influenza during regular 
seasons.
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